No image available for this title

LITERATURE

Benefit: Risk Profle of Budesonide in Obstructive Airways Disease


Airway infammation is a major contributing factor in both asthma and chronic obstructive pulmonary disease (COPD) and
represents an important target for treatment. Inhaled corticosteroids (ICS) as monotherapy or in combination therapy with
long-acting β2-agonists or long-acting muscarinic antagonists are used extensively in the treatment of asthma and COPD.
The development of ICS for their anti-infammatory properties progressed through eforts to increase topical potency and
minimise systemic potency and through advances in inhaled delivery technology. Budesonide is a potent, non-halogenated
ICS that was developed in the early 1970s and is now one of the most widely used lung medicines worldwide. Inhaled budesonide’s physiochemical and pharmacokinetic/pharmacodynamic properties allow it to reach a rapid and high airway efcacy
due to its more balanced relationship between water solubility and lipophilicit


Availability

Budesma-009Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
-
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous